Contact this trialFirst, we need to learn more about you.
Calcitonin Gene-Related Peptide (CGRP) Antagonist
Atogepant 30 mg +1 More for Migraine
Recruiting1 awardPhase 3
Little Rock, Arkansas
This study evaluated the efficacy, safety and tolerability of atogepant in participants with chronic migraine. This study included a 12-week treatment period.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service